Selective IgA deficiency is the most common primary immunodeficiency disease, affecting roughly 1 in 500 people in North America. Despite being so widespread, most people who have it never know, because about 70% of them experience no symptoms at all.
What Selective IgA Deficiency Actually Is
IgA is a type of antibody concentrated in the mucous membranes lining your respiratory tract, gut, and urinary system. It acts as a first line of defense, neutralizing bacteria and viruses before they can penetrate deeper into the body. In selective IgA deficiency, the immune system produces little to no IgA while other antibody types (IgG and IgM) remain at normal levels. A diagnosis is confirmed when serum IgA drops below 7 mg/dL with those other antibodies still in normal range.
The underlying problem happens at the cellular level. B cells, the white blood cells responsible for making antibodies, successfully switch to producing IgA on their surface but then fail to mature into cells that actually secrete it. Think of it like a factory that builds a product but never ships it. The B cells carry IgA on their outer membrane, yet they can’t release it into the body’s secretions where it’s needed. In roughly 10% of patients, this maturation failure traces back to a defect in a specific receptor (called TACI) that helps B cells complete their development. In other cases, shortages of certain signaling molecules that guide B cell maturation appear to be responsible.
Why Most People Never Notice It
Only about 30% of people with selective IgA deficiency develop symptoms tied to the condition. The rest are protected by backup immune mechanisms. Your body produces several types of antibodies, and when IgA is absent, other antibodies and immune defenses often compensate well enough that infections don’t become a recurring problem.
For the minority who do have symptoms, the most common issue is recurrent upper respiratory infections: frequent colds, sinus infections, and ear infections that seem to come back more often than normal. Some people also develop gastrointestinal infections or chronic diarrhea. These infections are typically mild to moderate rather than life-threatening, which is part of why the condition often flies under the radar for years.
Linked Autoimmune and Allergic Conditions
Selective IgA deficiency raises the risk of several other immune-related conditions. People with it are more likely to develop allergies, asthma, celiac disease, rheumatoid arthritis, and inflammatory bowel disease. The connection to celiac disease is particularly notable: routine celiac screening relies on measuring IgA-based antibodies, so people with IgA deficiency can get false-negative results on standard celiac blood tests. If you have IgA deficiency and suspect celiac disease, your doctor needs to use an alternative testing method.
About 5% of people initially diagnosed with selective IgA deficiency eventually progress to common variable immunodeficiency (CVID), a more serious condition where multiple types of antibodies drop to low levels. CVID is actually the most common symptomatic primary immunodeficiency, and it shares the same underlying biological roots as IgA deficiency. This progression is relatively uncommon, but it’s worth periodic monitoring.
Blood Transfusion Considerations
One practical concern for people with selective IgA deficiency involves blood transfusions. Some IgA-deficient individuals develop antibodies against IgA itself, and when they receive standard blood products containing IgA from a donor, those anti-IgA antibodies can theoretically trigger an allergic or anaphylactic reaction. In practice, this risk is very small. Fewer than 1 in 500,000 transfused blood components cause an IgA-related anaphylactic reaction, and even among IgA-deficient patients who carry anti-IgA antibodies, only about 1 in 100 actually experience a transfusion reaction.
Still, if you know you have IgA deficiency, it’s worth mentioning to medical staff before any procedure that might involve blood products. Some transfusion services can provide IgA-depleted or washed blood components when needed.
How It Compares to Other Immunodeficiencies
Primary immunodeficiencies as a group are dominated by antibody-related conditions, which account for about half of all cases. Within that category, selective IgA deficiency holds the top spot by prevalence, followed by CVID. The distinction matters because these two conditions sit on a spectrum. IgA deficiency is usually mild or silent, while CVID causes more frequent and severe infections and typically requires ongoing antibody replacement therapy. Interestingly, standard immunoglobulin replacement therapy isn’t used for isolated IgA deficiency, since the missing antibody isn’t well-replaced by infusion and most patients don’t need it.
For symptomatic patients, management focuses on treating infections promptly and monitoring for the autoimmune conditions that tend to cluster with the deficiency. There is no cure, but for the vast majority of people, selective IgA deficiency is a condition they live with comfortably, often without ever needing treatment beyond what any healthy person would receive for an occasional infection.